UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins

The Journal of pharmacology and experimental therapeutics, 2005-09, Vol.314 (3), p.1013

2005

Volltextzugriff (PDF)

Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer

Expert review of molecular diagnostics, 2005-09, Vol.5 (5), p.701-713

2005

Volltextzugriff (PDF)

Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

Journal of clinical pharmacology, 2007-06, Vol.47 (6), p.744-750

2007

Volltextzugriff (PDF)

Fever and antipyretic use in children

Pediatrics (Evanston), 2011-03, Vol.127 (3), p.580

2011

Volltextzugriff (PDF)

The effects of cocaine on cerebral metabolic function in periweanling rats: the roles of serotonergic and dopaminergic uptake blockade

Brain research. Developmental brain research, 1995-09, Vol.88 (2), p.158-170

1995

Volltextzugriff (PDF)

Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial

Journal of attention disorders, 2020-02, Vol.24 (3), p.402-413

2020

Volltextzugriff (PDF)

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Journal of neurology, 2023-08, Vol.270 (8), p.3862-3875

2023

Volltextzugriff (PDF)

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy

Clinical drug investigation, 2016-05, Vol.36 (5), p.341-356

2016

Volltextzugriff (PDF)

A Long-Term, Open-Label, Safety Study of Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD

Journal of attention disorders, 2020-02, Vol.24 (3), p.434-446

2020

Volltextzugriff (PDF)

Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients

Journal of the neurological sciences, 2023-12, Vol.455, p.121883, Article 121883

2023

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder

CNS drugs, 2017-11, Vol.31 (11), p.999-1014

2017

Volltextzugriff (PDF)

A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design

Postgraduate medicine, 2018-07, Vol.130 (5), p.481-493

2018

Volltextzugriff (PDF)

Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial

Journal of the peripheral nervous system, 2024-07

2024

Volltextzugriff (PDF)

A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD

Postgraduate medicine, 2019-04, Vol.131 (3), p.212-224

2019

Volltextzugriff (PDF)

Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study

Pediatric neurology, 2024-07, Vol.156, p.198-207

2024

Volltextzugriff (PDF)

Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment

Postgraduate medicine, 2018-01, Vol.130 (1), p.111-121

2018

Volltextzugriff (PDF)

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

The Journal of pharmacology and experimental therapeutics, 2009-11, Vol.331 (2), p.598

2009

Volltextzugriff (PDF)

Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults

International clinical psychopharmacology, 2013-03, Vol.28 (2), p.99

2013

Volltextzugriff (PDF)

P4-366: GSI-953, a potent and selective gamma-secretase inhibitor: Modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T781-T781

2008

Volltextzugriff (PDF)

P3-101: GSI-953, a potent and selective gamma-secretase inhibitor, modulates Abeta peptides in mice and humans: Translating the PK/PD biomarker relationships in different biological compartments between rodent and human

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T548-T548

2008

Volltextzugriff (PDF)

O3‐06‐07: GSI‐953 is a potent APP‐selective gamma‐secretase inhibitor for the treatment of Alzheimer's disease

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_5), p.P139-P139

2009

Volltextzugriff (PDF)

GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P139-P139

2009

Volltextzugriff (PDF)

The short- and long-term effects of chronic late postnatal blockade of the dopamine transporter on cerebral glucose utilization and dopamine D(1)/D(2) receptors in the rat brain

Frick, Glen Steven

1998

Volltextzugriff (PDF)

Human testicular androgen-binding protein shares immunodeterminants with serum testosterone-estradiol-binding globulin

Endocrinology (Philadelphia), 1984-04, Vol.114 (4), p.1395-1401

1984

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(24)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(11)
Adult
(8)
Male
(7)
Female
(6)
Neurology
(6)
Pharmacology & Pharmacy
(6)
Neurosciences
(5)
Neurosciences & Neurology
(5)
Adolescent
(4)
Attention Deficit Disorder With Hyperactivity - Drug Therapy
(4)
Clinical Neurology
(4)
Psychiatry
(4)
Adolescents
(3)
Animals
(3)
Attention-Deficit/hyperactivity Disorder
(3)
Dose-Response Relationship, Drug
(3)
Double-Blind Method
(3)
Duration Of Effect
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins

Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer

Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

Fever and antipyretic use in children

The effects of cocaine on cerebral metabolic function in periweanling rats: the roles of serotonergic and dopaminergic uptake blockade

Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy

A Long-Term, Open-Label, Safety Study of Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD

Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients

Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder

A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design

Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial

A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD

Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study

Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults

P4-366: GSI-953, a potent and selective gamma-secretase inhibitor: Modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans

P3-101: GSI-953, a potent and selective gamma-secretase inhibitor, modulates Abeta peptides in mice and humans: Translating the PK/PD biomarker relationships in different biological compartments between rodent and human

O3‐06‐07: GSI‐953 is a potent APP‐selective gamma‐secretase inhibitor for the treatment of Alzheimer's disease

GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease

The short- and long-term effects of chronic late postnatal blockade of the dopamine transporter on cerebral glucose utilization and dopamine D(1)/D(2) receptors in the rat brain

Human testicular androgen-binding protein shares immunodeterminants with serum testosterone-estradiol-binding globulin

Suchergebnisse filtern